COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Preventing Invasive Cervical Cancer: The Importance of Expectant Management in Young Women With High-grade Pre-cancerous Lesions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03920800
Recruitment Status : Recruiting
First Posted : April 19, 2019
Last Update Posted : April 19, 2019
Sponsor:
Information provided by (Responsible Party):
Catherine Vanpachterbeke, Brugmann University Hospital

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

Lesions classified as "High Grade Squamous Intra-epithelial Lesions" (HSIL) are pre-cervical lesions of the cervix, induced by infection with the Human Papilloma Virus (HPV). The detection and proper management of these lesions greatly reduces the incidence of invasive cervical cancer.

Pap smear remains the most effective tool for early detection of low and high-grade cervical lesions. In Belgium, screening for cervical cancer is recommended every 3 years for women between 25 and 65 years old.

HPV is a virus who possesses certain oncogenic genes who have the ability to inactivate tumor suppressor genes in the host cell. This promotes a tumorigenesis process within the tissues affected by the virus. The majority of human papillomavirus infections are transient and spontaneously cleared by host defense mechanisms, especially in the first two years after exposure. However, 10-20% of infections persist latently and may eventually lead to progression to invasive cervical cancer.

Even high-grade lesions kan naturally be cleared, even more so if the patient is young and immuno-competent. Therefore, the management of HSIL lesions in young women has been modified and consists of adopting mainly a conservative attitude, with controls every 6 months for 2 years. This management makes it possible to avoid unnecessary conizations of the cervix which, in young nulliparous patients, are not devoid of heavy obstetric consequences during subsequent pregnancies (premature birth, perinatal mortality). Cervical conization will only be considered for lesions that progress during follow-up or that persist beyond 2 years. However, this type of follow-up requires that patients be compliant.

Our study has two main objectives:

  • to determine the compliance of CHU Brugmann Hospital patients who have been proposed a conservative strategy for the management of HSIL lesions.
  • to identify the predictive factors for the persistence and / or progression of high-grade pre-cancerous dysplastic lesions.

Condition or disease Intervention/treatment
High-Grade Squamous Intraepithelial Lesions Other: Data extraction from medical files Biological: Immunohistochemistry

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Preventing Invasive Cervical Cancer: The Importance of Expectant Management in Young Women With High-grade Pre-cancerous Lesions
Actual Study Start Date : March 1, 2019
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cervical Cancer

Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
Conservative management - progression
Young women with high grade pre-cancerous lesions, followed within the CHU Brugmann Hospital according to a conservative attitude, with progressive lesions or lesions remaining present after 2 years of follow-up.
 Other: Data extraction from medical files
Data extraction from medical files

Biological: Immunohistochemistry
Immunohistochemistry with Ki67 and p16 antibodies on residual samples, if this had not been foreseen in the standard of care management of the patient.
Conisation
Young women with high grade pre-cancerous lesions, followed within the CHU Brugmann Hospital by means of conisations.
 Other: Data extraction from medical files
Data extraction from medical files

Biological: Immunohistochemistry
Immunohistochemistry with Ki67 and p16 antibodies on residual samples, if this had not been foreseen in the standard of care management of the patient.
Conservative management - spontaneous regression
Young women with high grade pre-cancerous lesions, followed within the CHU Brugmann Hospital according to a conservative attitude, who showed a spontaneous regression of the lesions during the 2 years follow-up.
 Other: Data extraction from medical files
Data extraction from medical files

Biological: Immunohistochemistry
Immunohistochemistry with Ki67 and p16 antibodies on residual samples, if this had not been foreseen in the standard of care management of the patient.


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Patient observance [ Time Frame: Every six months over a period of 24 months ]

    Numeric value: 1 (optimal), 2 (acceptable), 3 (absent).

    Groups having benefited from a conservative attitude: Optimal compliance: 4 consultations in 24 months and / or indication of conization. Acceptable compliance: 2 to 3 consultations in 24 months. Observance absent: 0 to 1 consultation in 24 months. Groups having benefited from conization:

    Optimal compliance: 2 consultations after conisation. Acceptable compliance: 1 after consultation. Observance absent: 0 consultation after conisation.


  2. Cytologic results of the cervico-uterine smear. [ Time Frame: Every six months over a period of 24 months ]
    Cytologic results of the cervico-uterine smear. Diagnose established by the anatomo-pathologist.

  3. Histologic results of the cervical biopsies [ Time Frame: Every six months over a period of 24 months ]
    Histologic results of the cervical biopsies.Diagnose established by the anatomo-pathologist.

  4. Extent of dysplastic lesions [ Time Frame: Every six months over a period of 24 months ]
    Defined as the number of quadrants reached by the lesion.

  5. Endocervix damage [ Time Frame: Every six months over a period of 24 months ]
    Is the endocervix affected by the HSIL lesion (yes or no) ?

  6. Immuno-histologic results Ki67 [ Time Frame: Every six months over a period of 24 months ]
    Percentage of Ki67 antibody reactivity on the cervix biopsies

  7. Immuno-histologic results p16 [ Time Frame: Every six months over a period of 24 months ]
    Percentage of p16 antibody reactivity on the cervix biopsies


Secondary Outcome Measures :
  1. Gestity [ Time Frame: Every six months over a period of 24 months ]
    Total number of pregnancies

  2. Parity [ Time Frame: Every six months over a period of 24 months ]
    Total number of children born

  3. Age at first patient visit [ Time Frame: 1 day ]
    Age at first patient visit

  4. HIV status [ Time Frame: Every six months over a period of 24 months ]
    HIV positive or negative

  5. Smoking status [ Time Frame: Every six months over a period of 24 months ]
    Smoking or non smoking

  6. Response time to the convocation for colposcopy [ Time Frame: Up to 24 months ]
    Time between the patient's appointment and the receipt of the convocation for colposcopy

  7. HPV status [ Time Frame: Every six months over a period of 24 months ]
    Positive or negative for HPV virus

  8. Quality of colposcopic examinations [ Time Frame: Every six months over a period of 24 months ]
    Defined as satisfactory or unsatisfactory (junction area completely seen or not seen).


Biospecimen Retention:   Samples Without DNA
  • Pap smear
  • Cervical biopsies

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   All
Sampling Method:   Non-Probability Sample
Study Population
Young women followed within the CHU Brugmann Hospital for HSIL lesions.
Criteria

Inclusion Criteria:

  • Patients followed within the CHU Brugmann Hospital (no private practices).
  • HSIL lesions confirmed by anatomopathologic analysis on cervical biopsies or cone specimen without evidence of invasive lesions

Exclusion Criteria:

  • Invasive lesions
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03920800


Contacts
Layout table for location contacts
Contact: Georges Salem Wehbe, MD 3224772010 Georges.SALEMWEHBE@chu-brugmann.be

Locations
Layout table for location information
Belgium
CHU Brugmann Recruiting
Brussels, Belgium, 1020
Contact: Georges Salem Wehbe, MD         
Sponsors and Collaborators
Catherine Vanpachterbeke
Investigators
Layout table for investigator information
Principal Investigator: Georges Salem Wehbe, MD CHU Brugmann
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Catherine Vanpachterbeke, Head of clinic, Brugmann University Hospital
ClinicalTrials.gov Identifier: NCT03920800    
Other Study ID Numbers: CHUB-Salem Wehbe
First Posted: April 19, 2019    Key Record Dates
Last Update Posted: April 19, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Uterine Cervical Neoplasms
Squamous Intraepithelial Lesions of the Cervix
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
 Neoplasms
Uterine Cervical Diseases
Uterine Diseases
Uterine Cervical Dysplasia
Precancerous Conditions